Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraoperative Photodynamic Therapy of Glioblastoma
NCT03048240Completed
- Sponsor
- CHU de Lille
- Start
- May 2017
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of 5-aminolevulinic acid in glioblastoma (GBM), sponsored by CHU de Lille. Primary endpoint: Number of Patients having the full 'PerPDT' treatment with unacceptable and unexpected toxicities (grade >= 3) at 1 month. Started May 2017; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03048240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03048240.